TScan Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Two-year relapse data from ALLOHA™ Phase 1 heme trial to be presented by end of year WALTHAM, Mass., Aug. 12, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today reported financial results for the second quarter ended June 30, 2025, and provided a corporate update. "We expect to dose our first solid tumor patients with m ...